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Abstract: Neoadjuvant chemotherapy in osteosarcoma increased the long-term survival of patients with localized 
disease considerably but metastasizing osteosarcoma remained largely treatment resistant. Neuropilins, trans-
membrane glycoproteins, are important receptors for VEGF dependent hyper-vascularization in tumor angiogen-
esis and their aberrant expression promotes tumorigenesis and metastasis in many solid tumors. Our analysis of 
Neuropilin-1 (NRP1) and Neuropilin-2 (NRP2) immunostaining in a tissue microarray of 66 osteosarcoma patients 
identified NRP2 as an indicator of poor overall, metastasis-free and progression free survival while NRP1 had no 
predictive value. Patients with tumors that expressed NRP2 in the absence of NRP1 had a significantly worse prog-
nosis than NRP1-/NRP2-, NRP1+ or NRP1+/NRP2+ tumors. Moreover, patients with overt metastases and with NRP2-
positive primary tumors had a significantly shorter survival rate than patients with metastases but NRP2-negative 
tumors. Furthermore, the expression of both NRP1 and NRP2 in osteosarcoma cell lines correlated to a variable 
degree with the metastatic potential of the respective cell line. To address the functional relevance of Neuropilins 
for VEGF signaling we used shRNA mediated down-regulation and blocking antibodies of NRP1 and NRP2 in the 
metastatic 143B and HuO9-M132 cell lines. In 143B cells, VEGFA signaling monitored by AKT phosphorylation was 
more inhibited by blocking of NRP1, whereas in HuO9-M132 cells NRP2 blocking was more effective indicating that 
NRP1 and NRP2 can substitute each other in the functional interaction with VEGFR1. Altogether, these data point 
to NRP2 as a powerful prognostic marker in osteosarcoma and together with NRP1 as a novel target for tumor-
suppressive therapy.
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Introduction
Osteosarcoma (OS) is the most frequent prima-
ry bone tumor with a peak incidence in the sec-
ond decade of life. It is the major cause of can-
cer-related death in children in adolescence [1]. 
The introduction of multi-agent chemotherapy 
in the 1970s and refinements in the surgical 
techniques remarkably increased the long-term 
survival rate of patients with localized OS to 
approximately 60%. However, little has changed 
for patients with metastatic disease and their 
long-term survival rate remained at 25-30% [2]. 
Therefore, a more detailed understanding of 
the pathophysiological mechanisms in OS 
metastasis and of the biological roles of key 
regulators, considered as prognostic biomark-
ers, is needed for the development of new 
treatment strategies effectively targeting the 
complex metastatic processes in order to im- 
prove the outcome of OS patients with meta-
static disease.
The Neuropilins (NRPs) NRP1 and NRP2 are 
type I transmembrane glycoproteins that have 
an important role in development, immunity 
and cancer [3-11]. NRP1 and NRP2 exhibit 44% 
amino acid sequence homology, share domains 
of similar structure and bind an overlapping set 
of ligands [3-6, 10]. NRP1 and/or NRP2 are 
expressed in a variety of cells including neu-
rons, endothelial cells, hepatocytes, melano-
cytes, osteoblasts, dendritic cells, thymocytes 
and regulatory T cells [6, 12-18]. They form 
homo- and heterodimers [19] and, as corecep-
tors for various guidance molecules and growth 
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factors, for example Semaphorin and proangio-
genic VEGF isoforms (namely VEGF A), they 
enhance the biological effects of these effector 
molecules and are therefore important for 
axonal guidance and angiogenesis [20, 21]. 
NRPs are capable to bind the different pro-
angiogenic isoforms of VEGF and to recruit 
these ligands to the cell surface where they 
associate with VEGF receptors and form terna-
ry VEGF/NRP/VEGFR complexes [20, 22]. NRPs 
alone are unable to activate signalling path-
ways, but they promote the formation of and 
stabilize ternary VEGF/NRP/VEGFR signaling 
complexes [23-25].
Even though the role of Neuropilins in physio-
logical processes is well described, less is 
known on their role in cancer biology. NRPs 
were reported to be important for VEGF depend-
vestigated in vitro the importance of Neuropilins 
in VEGFR signaling in the human metastatic 
143B and HuO9-M132 OS cell lines.
Materials and methods
Charactersitics of OS patients 
OS tissue samples were collected from 66 
patients between June 1989 and June 2005 
for diagnostic purposes The samples were fixed 
in 4% buffered formalin and embedded in par-
affin. All patients were diagnosed with high-
grade OS, according to valid WHO classifica-
tions. For detailed characteristics of the pa- 
tients refer to Table 1. Most patients received 
standard neoadjuvant chemotherapy (52 were 
treated, 12 were not treated and 2 patients 
lack information about chemotherapy respo- 
Table 1. Clinical characteristics of high grade osteosarcoma pa-
tients included in this study
n %
Totala 66 100
NRP1 positivea 7 11
NRP1 negativea 58 89
NRP2 positive 7 11
NRP2 negative 59 89
Gender female 23 35
male 43 65
Age (years) < 10 11 17
10-24 39 59
> 24 16 24
Tumor type Osteoblastic 45 68
Chondroblastic 11 17
Fibroblastic 6 9
Telangiectatic 4 6
Anatomical Site Tibia/fibula/calcaneus 21 32
Femur 24 36
Humerus/ulna 6 9
Jaws/facies/vertebrae column/pelvis 15 23
Chemotherapy response Responders 29 44
Non-responders 23 35
No neoadjuvant chemotherapy 12 18
Missing information 2 3
Metastasis No metastasis 43 65
Total metastasis 23 35
Metastasis at diagnosis 5 8
Metastasis after diagnosis 18 27
aThe total number of patients evaluated for NRP1 staining = 65.
ent hyper-vascularisation in 
tumour angiogenesis [8]. The 
expression of NRPs varies con-
siderably from one tumor to 
another, but their aberrant 
expression has been shown to 
promote tumorigenesis and 
metastasis in vivo in many 
solid tumors [5-7, 26]. The 
expression of NRPs was shown 
to be critical for autocrine regu-
lation of tumor cell activities 
including survival, growth and 
migration [27-30]. Since VEGF 
is considered a prime mediator 
of angiogenesis and is exp- 
ressed in different isoforms, 
with some of them being 
ligands of NRPs, it is of great 
interest to investigate their 
expression in the light of Ne- 
uropilin mediated cancer pro-
gression. In OS, several stud-
ies have shown that the expres-
sion of VEGF in tumor tissue is 
a strong prognostic indicator 
for poor overall survival [31-
33]. However, little is known 
about the expression and role 
of Neuropilins in OS progres-
sion. Therefore we investigated 
in the present study for the first 
time the expression of NRP1 
and NRP2 in an OS tissue mi- 
croarray and in a panel of os- 
teosarcoma cell lines, and in- 
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nse) according to standard protocols (in course 
of COSS-91 and COSS-96) with methotrexate, 
cisplatin, ifosfamide and doxorubicin. Chemo- 
therapy-induced tumor necrosis was evaluated 
according to the criteria of Salzer-Kuntschik 
[34]. Patients who showed tumor necrosis of 
90% or higher were considered as responders, 
patients with tumor necrosis below 90% were 
classified as non-responders. The study was 
performed in accordance with the guidelines 
provided by the local ethic committee (approval 
reference number StV 41-2005).
Tissue microarray and immunohistochemistry
Tissue cores with a diameter of 0.6 mm were 
isolated from paraffin-embedded formalin fixed 
tissue and transferred into a recipient paraffin 
block as described earlier [35, 36]. Tissue co- 
res were selected by an experienced patholo-
gist based on haematoxylin and eosin (H&E) 
stainings of tissue sections. A minimum of two 
cores per sample were selected, representing 
the tumor heterogeneity with more than 95% 
reliability [6, 37]. 
Two µm or 4.5 µm sections of the tissue micro-
array (TMA) were de-paraffined in xylene and 
heated with the pretreatment buffer according 
to standard immunohistochemical protocols. 
The following primary antibodies were used for 
immunostaining: Rabbit polyclonal anti-NRP1 
(1:50, ECM Biosciences LLC, Versailles, KY, 
USA) and rabbit polyclonal anti-NRP2 (H-300, 
1:50, Santa Cruz Biotechnology, Inc., Dallas, 
TX, USA). Primary antibodies were detected us- 
ing standard indirect immunoperoxidase reac-
tions and 3,3’-Diaminobenzidine (DAB) tetrahy-
drochloride as a substrate. Antibody binding 
was visualized with a iVIEW DAB Kit (Ventana 
Medical Systems Tucson, Arizona, USA) yielding 
a brown precipitate.
Analysis of the TMA was performed in a semi-
quantitative manner. We developed our own 
MATLAB-analysis software tool (R2010b; 
Mathworks Inc., Natick, MA, USA) based on the 
principle of color deconvolution by Ruifrok and 
Johnston [38]. This tool was used to grade the 
immunostainings according to Gvozdenovic et 
al. [39]. Briefly, non-detectable immunostaining 
was considered as grade 1 whereas“weak 
staining” was defined as grade 2 and “strong 
staining” as grade 3. Based on the grading of 
2-3 cores per tissue, the average staining inten-
sity was calculated and an average grading 
above 1.5 was classified as NRP1/NRP2 posi-
tive and any value lower or equal than 1.5 was 
considered NRP1/NRP2 negative.
Statistical analysis
Overall survival, progression-free and metasta-
ses-free survival were calculated using Kaplan–
Meier curves and statistical significance was 
assessed by log-rank tests. Overall survival 
was defined as percentage of patients who 
were alive at the latest follow-up. Progression-
free survival (PFS) was defined as the percent-
age of patients who did not show a progression 
of disease between completion of the primary 
treatment and the last follow-up and metasta-
ses-free survival (MFS) denoted the percentage 
of patients who were free of metastases at the 
last follow-up.
Cell lines
MG-63 cells were kindly provided by Dr. G. 
Sarkar (Mayo Clinic, Rochester, MN), and MG- 
63 M6 and M8 cells by Dr. W. T. Zhu (Tongji 
Hospital, Huazhong University of Science and 
Technology, Wuhan, China). HuO9 cells and the 
sublines H3, M112, M132 were obtained from 
Dr. M. Tani (National Cancer Center Hospital, 
Tokyo, Japan). HOS, MNG/HOS and 143B cells 
were purchased from the American Type 
Culture Collection (ATCC, Rockville, MD). The 
cell lines MG63 and HOS as well as their deriva-
tives were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) and F12 medium (Gibco, 1:1) 
supplemented with 10% FCS. HuO9 cells and 
the respective sublines HuO9-H3, -M112 and 
M132 were cultured in RPMI 1640 medium 
(Gibco, Basel, Switzerland), supplemented with 
10% heat-inactivated fetal calf serum (FCS) 
and 1% glutamine (Invitrogen). Cells were cul-
tured at 37°C in an atmosphere of 5% CO2 and 
95% relative humidity.
Isolation of RNA and cDNA synthesis
Total RNA was isolated from cells grown to 
approximately 80% confluence with TRI reagent 
(Sigma-Aldrich, St. Louis, MO) as recommend-
ed by the supplier. The RNA was quantified by 
optical density measurements at 260 and 280 
nm in a UV-spectrometer (Beckman Instruments 
Inc., Fullerton, CA). The integrity of RNA was 
assessed by standard agarose gel electropho-
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resis. cDNA was reverse transcribed from 1 μg 
of total RNA with the Stratagene first strand 
synthesizing system and random primers (Str- 
atagene, La Jolla, CA) according to the protocol 
supplied by the manufacturer. 
Cloning of shRNA constructs
Oligonucleotide sequences 5’-ATGCGAATGG- 
CTGATTCAG-3’ and 5’-CTGGAGAACATATATGC-3’ 
designed to target NRP1 and NRP2 transcripts, 
respectively, were cloned into the pSIREN-Ret-
roQ retroviral vector (Clontech Laboratories, 
USA). A control vector containing a scrambled 
oligonucleotide sequence was provided by the 
manufacturer. 143B cells were infected with 
these vectors and neomycin resistant cells 
were selected. The efficiency of NRP1 and 
NRP2 silencing was examined on Western blots 
of total cell extracts.
Polymerase chain reaction
PCR was performed in a total volume of 50 μl 
containing 2 μl of cDNA, equivalent to a con-
centration of 5 ng/μl of RNA in the reverse tran-
scription (RT) reaction, 5 μl of 10x Taq Buffer 
advanced (Eppendorf, Hamburg, Germany), 1 
μl of dNTPs (10 mM), 0,3 μl of each primer (0.2 
μM), 0.5 μl (2.5 U) Taq DNAPolymerase (Epp- 
endorf) with initial denaturation at 94°C for 3 
min followed by 35 cycles of denaturation at 
94°C for 40 s, annealing at the primer-depend-
ent temperature for 40 s and elongation at 
72°C for 20 s. PCR was completed by elonga-
tion at 72°C for 7 min. The annealing tempera-
tures were 67°C for NRP1 and NRP2, 67°C for 
VEGFR-1 and VEGFR-2 64°C for VEGF and 66°C 
for GAPDH. The sequences of primers are 
shown in Supplemental Table 1. PCR products 
were analysed by 1.5% agarose gel electropho-
resis at 120 V for approximately 90 min in the 
presence of ethidium bromide (0.1%). 
RT/PCR products of transcripts encoding the 
housekeeping gene glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) were used as 
controls for cDNA input in individual PCR 
reactions. 
Western blot analysis
Proteins were extracted from indicated cell 
lines and immunoblotted as reported [40]. 
Rabbit antibodies to VEGF-A, VEGFR1, VEGFR2, 
NRP1, NRP2, phospho-Akt, Akt (Cell Signaling 
Technology, Danvers, MA, USA) and mouse 
antibodies to β-actin (Santa Cruz) were used at 
final dilutions of 1:1000. Subsequently, immu-
noblots were incubated at RT for 1 h with sec-
ondary horseradish peroxidase conjugated 
anti-rabbit or anti mouse IgG (Santa Cruz Bi- 
otechnology Inc., Heidelberg, Germany) at final 
dilutions of 1:2000. The proteins were then 
visualized with Immobilon chemiluminescence 
substrate (Millipore, Billerica) and quantified 
with a VersaDoc™ Imaging System (Bio-Rad 
Laboratories, Munich, Germany). In VEGF stim-
ulation and NRP1 and -2 blocking experiments, 
the cells were pre-incubated at 37°C for 1 h 
with 20 µg/ml of NRP1 or NRP2 blocking anti-
bodies (RD systems, USA) and subsequently 
stimulated at 37°C for 5 min with 10 ng/ml 
VEGF-A165 (Cell Signaling Technology, Danvers, 
MA, USA) in the presence of the blocking anti-
bodies. The cells were then washed once with 
ice cold PBS and processed as described 
above.
Results
NRP2 expression in primary tumor tissue cor-
relates with poor prognosis for osteosarcoma 
patients 
Osteosarcomas are highly vascularized tumors 
and several studies showed correlations be- 
tween VEGF and VEGFR expression and poor 
survival [31-33]. Based on the relevance of 
Neuropilins for VEGFR-1 signaling, they can be 
considered as potential prognostic markers in 
osteosarcoma. Consequently, we analyzed, by 
immunohistochemistry, the expression of NRP1 
and NRP2 in primary tumor tissue on an OS tis-
sue microarray (TMA) and performed Kaplan-
Meier survival analyses.
Characteristics of the patients included in the 
TMA are summarized in Table 1. Sixty-five per-
cent of the patients investigated were male and 
the largest subgroup of patients was that of 
adolescents of between 10 and 24 years of age 
(59%) followed by adults (24%, range: 27-66 
years of age) and children (17%, range: 2-9 
years of age). The majority of patients (68%) 
included in this study suffered from osteoblas-
tic OS, and primary tumors were mainly located 
in long bones such as the femur (36%) or the 
tibia/fibula/calcaneus (32%). Seventy-nine per-
cent of the patients received neoadjuvant che-
Clinical and biological relevance of neuropilin 1 and 2 in osteosarcoma
644 Am J Transl Res 2015;7(3):640-653
Clinical and biological relevance of neuropilin 1 and 2 in osteosarcoma
645 Am J Transl Res 2015;7(3):640-653
motherapy. In the remaining group of patients, 
some were not treated because of their condi-
tion and for others the clinical information was 
missing. Furthermore, 65% of the patients re- 
mained metastases-free during the course of 
the disease, 8% presented with metastases at 
diagnosis and 27% developed metastases dur-
ing follow up. Tissue specimens of 65 patients 
could be analyzed for immunoreactive NRP1 
and/or NRP2. In the tumor of one additional 
patient only NRP2 immunostaining could be 
assessed. NRP1 immunostaining was found in 
tumors of 7 patients (11%) and an equal num-
ber of patients had tumors that stained for 
NRP2. 
TMA tissue cores representative for positive or 
negative NRP1 and NRP2 immunostaining are 
shown in Figure 1A and 1B, respectively. Both, 
Figure 1A and 1B show in brown, extra-nuclear, 
positive staining, and staining considered as 
negative appears blue. A supplementary Figure 
(Supplemental Figure 1) shows representative 
high-resolution images of weak, moderate and 
strong NRP1 and NRP2 immunostaining of TMA 
cores. In Figure 1 is illustrated overall survival 
(Figure 1C and 1F), metastases-free (Figure 1D 
and 1G) and progression-free survival (Figure 
1E and 1H) of patients who showed either posi-
tive or negative staining for NRP1 or for NRP2, 
respectively. Overall, metastasis-free and pro-
gression-free survival of patients with NRP1 
positive tumors was not significantly different 
from that of patients with NRP1 negative 
tumors. However, patients with tumors that 
showed positive NRP2 immunostaining had a 
significantly shorter overall (P = 0.0012), me- 
tastases-free (P = 0.042) and progression-free 
survival (P = 0.0051) than those with NRP2 
negative tumors, suggesting that the expres-
sion of NRP2 in OS primary tumors is a robust 
predictor for poor survival. Therefore, Kaplan-
Meier survival analyses based on NRP2 immu-
nostaining of primary tumors were extended to 
subgroups of patients. These included patients 
with metastatic disease and non-responders to 
chemotherapy. Interestingly, patients with 
metastases and positive immunostaining for 
NRP2 in primary tumors exhibited a significant-
ly shorter survival than those with metastases 
and NRP2 negative tumors (Figure 1I). The 
data also showed a tendency to shorter surviv-
al of non-responders with NRP2 positive tumors 
compared to non-responders with NRP2 nega-
tive tumors, but the difference was not statisti-
cally significant (Figure 1J). The predictive 
power of NRP2 for OS patient survival was fur-
ther emphasized by the results presented in 
Figure 1K. Interestingly, patients with tumors 
staining positive for NRP2 but negative for 
NRP1 had a significantly (P = 0.0031) shorter 
survival than all other patients with NRP1+/
NRP2+, NRP1+/NRP2-, NRP1-/NRP2- staining 
patterns in their primary tumors. All findings 
taken together imply that the expression of 
NRP2, unlike that of NRP1, in OS primary 
tumors correlates with a poor prognosis for the 
patients, irrespective of metastatic or non-met-
astatic disease, the as of yet best established 
predictor for OS outcome.
Neuropilin 1 and Neuropilin 2 are differentially 
expressed in osteosarcoma cell lines
Neuropilins have been reported to play an 
important role as co-receptors for VEGF in 
tumor growth and metastasis [22]. In the pres-
ent study, the expression pattern of NRP1 and 
NRP2 was investigated in several OS cell line 
systems consisting of parental cell lines with 
low metastatic potential and corresponding 
derivative sub-lines with high metastatic poten-
tial. The different OS cell lines showed quite a 
heterogeneous pattern of NRP1 and NRP2 
expression at the mRNA (Figure 2A) as well as 
at the protein level (Figure 2B). Interestingly, 
the highly metastatic sub-lines, except for the 
Figure 1. Prognostic power of NRP1 and NRP2 immunohistochemistry in a human osteosarcoma tissue microar-
ray assessed by Kaplan-Meier survival analysis: Representative images of NRP1 (A) and NRP2 (B) positive and 
negative tissue cores, respectively. Overall survival (C), metastases free survival (D) and progression free survival 
(E) of patients with detectable or non-detectable NRP1 expression in primary tumor tissue. Overall survival (F), 
metastases free survival (G) and progression free survival (H) of patients with detectable or non-detectable NRP2 
expression in primary tumor tissue. (I) OS patients with metastatic disease and detectable NRP2 have a shorter 
survival than those with non-detectable NRP2. (J) OS patients with a poor response to neoadjuvant chemotherapy 
(non-responders) and detectable NRP2 have a shorter survival than non-responders with non-detectable NRP2. (K) 
OS patients with detectable NRP2 and non-detectable NRP1 in their primary tumors have a shorter survival than 
all other patients (with and without metastases and responders and non-responders) with other patterns of NRP1 
and NRP2 expression. 
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MG63 derivatives, showed higher expression of 
Neuropilins than their parental cell lines, par-
ticularly at the protein level. In addition, the 
highly metastatic 143B and the HuO9-H3, 
-M112 and -M132 cell lines showed higher lev-
els of both NRP1 and NRP2 protein compo-
nents than the respective parental HOS and 
HuO9 cell lines, which points to potentially 
important roles of NRP1 and NRP2 in the meta-
static process in OS. 
VEGF and VEGF receptors are expressed in 
osteosarcoma cell lines
In view of postulated malignancy enhancing 
properties of NRP1 and -2 as co-receptors of 
VEGF in interaction with VEGFR-1 and VEGFR-2 
[22], we next analyzed the expression of VEGF 
A, which has been thoroughly described as an 
important ligand for Neuropilin 1 and 2 [22, 
41], and of its receptors VEGFR-1 and VEGFR-2 
in the osteosarcoma cell lines investigated in 
the present study (Figure 3). VEGF A exists as 
different isoforms that are encoded by alterna-
tively spliced primary VEGF A gene transcripts. 
Among the different splice variants of VEGF A, 
we analyzed the expression of the isoforms 
VEGF-A121, 145, 165 and 206 that contain domains 
required for the interaction with Neuropilins. 
Among these splice variants, transcripts for 
VEGF-A165, which is known to be the most 
potent VEGF A isoform [41], were uniformly 
expressed together with those encoding VE- 
Figure 2. Differential expression of NRP1 and NRP2 in human osteosarcoma cell lines at the mRNA and protein lev-
el: A. Semi-quantitative RT-PCR analysis of NRP1, NRP2 and GAPDH (reference) encoding RNA in total RNA isolated 
from parental low-metastatic MG63, HOS and HuO9 and respective metastatic MG63M6 and MG63M8, MNNG/
HOS and 143B, and HuO9-H3, HuO9-M112 and HuO9-M132 sublines. B. Western blot analysis of NRP1 and NRP2 
levels in total protein extracts of indicated cell lines, β actin was used as protein loading control. 
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GF-A121 in all 10 osteosarcoma cell lines (Figure 
3A). These findings were consistent with com-
parable levels of VEGF A immunoreactive com-
ponents detected on Western blots of protein 
extracts of the 10 cell lines investigated (Figure 
3B). Similarly, the VEGFR-1 was also found 
expressed at the transcript and the protein 
level in all tested cell lines and, interestingly, 
with a tendency for higher levels in the more 
aggressive cell lines (Figure 3A and 3B). VEGFR-
2 encoding mRNA, on the other hand, was only 
detected in the three cell lines of the HOS sys-
Figure 3. Differential expression of VEGFA and VEGF receptors in human osteosarcoma cell lines at the mRNA and 
protein level: A. Semi quantitative RT-PCR analysis of the expression of VEGFA isoform, VEGFR1 and VEGFR2 and 
GAPDH (reference) encoding RNA in total RNA isolated from parental low-metastatic MG63, HOS and HuO9 and re-
spective metastatic MG63M6 and MG63M8, MNNG/HOS and 143B, and HuO9-H3, HuO9-M112 and HuO9-M132 
sublines. B. Western blot analysis of VEGFA, VEGFR1 and VEGFR2 levels in total protein extracts of indicated cell 
lines, β-actin was used as a protein loading control. 
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tem and, unexpectedly, it remained un-detect-
able at the protein level. 
Antibody blocking and/or downregulation by 
shRNA of NRP1/NRP2 in OS cell lines inhibits 
VEGFR1-mediated AKT phosphorylation 
Even though Neuropilins are not linked to intra-
cellular signaling cascades, it has been shown 
in various cell types that the Neuropilins, when 
associated as co-receptors with VEGF recep-
tors, facilitate downstream signaling of VEGFR/
VEGF/NRP ternary complexes [9, 22, 24]. NRP1 
or NRP2 blocking antibodies that interfere with 
VEGF binding and thereby prevent the forma-
tion of VEGFR1/VEGF/NRP ternary complexes 
are expected to inhibit VEGFR1-mediated down-
stream signaling. To test this hypothesis, we 
pre-incubated serum-starved 143B cells in the 
absence and presence of NRP1 or NRP2 block-
ing antibodies and subsequently stimulated the 
cells with 10 ng/ml VEGF-A165 and analyzed 
AKT phosphorylation and NRP1 and NRP2 
expression on Western blots (Figure 4A). VEGF 
stimulated the phosphorylation of AKT approxi-
mately 4-fold and pre-incubation of the cells 
with 20 µg/ml NRP1 antibody reduced the 
response significantly (P ≤ 0.05) by approxi-
mately 30%. Interestingly, pre-incubation with 
20 µg/ml NRP2 blocking antibodies had no 
inhibitory effect on VEGF-evoked AKT phos-
phorylation in 143B cells. However, in HuO9- 
M132 cells, the result was just the opposite 
(Figure 4B). In these cells, VEGF stimulated AKT 
phosphorylation approximately 3-fold and pre-
incubation with 20 µg/ml NRP2 antibodies 
inhibited the response significantly (P ≤ 0.05) 
by approximately 30%. NRP1 blocking antibod-
ies, however, had no effect on VEGF-stimulated 
AKT phosphorylation. In both, the 143B and the 
HuO9-M132 cell lines, the treatment with NRP1 
or NRP2 antibodies did not affect respective 
receptor expression levels (Figure 4A and 4B). 
The importance of NRP1 and NRP2 in VEGF-
stimulated AKT phosphorylation in 143B cells 
was further investigated in cells in which the 
expression of NRP1 or NRP2 was selectively 
suppressed by stable expression of respective 
specific shRNAs. In these 143B-shNRP1 and 
143B-shNRP2 cell lines, we repeated the ex- 
periments carried out with the non-manipulat-
ed 143B cells described above and used 
scrambled shRNA expressing 143B cells as a 
control (Figure 4C and 4D). Stable expression 
of NRP1-targeting shRNA in 143B cells reduced 
the level of NRP1 expression to approximately 
20% of that detected in scrambled shRNA 
transduced 143B cells (control cells) and de- 
creased, in parallel and significantly (P ≤ 0.05, 
n = 3), the VEGF-A165-stimulated phosphoryla-
tion of AKT to approximately 60% of that 
observed in control cells (Figure 4C) and to a 
level that was approximately 3-times higher 
than that in non-stimulated 143B-shNRP1 
cells. Antibody blocking of NRP2 in these cells 
further reduced VEGF-A165 stimulated AKT 
phosphorylation significantly (P ≤ 0.05) by 
approximately 25% compared to non-blocked 
cells. In 143B cells that stably expressed NRP2-
targeting shRNA the level of NRP2 expression 
was downregulated to approximately 10% of 
that detected in scrambled shRNA transduced 
143B cells (control cells).  Interestingly, the 
stimulation of AKT phosphorylation by 10 ng/
ml VEGF-A165 in 143B-shNRP2 cells was only 
decreased to 80% of that observed in control 
cells, which was approximately 4-times higher 
than in non-stimulated 143B-shNRP2 cells. 
Antibody blocking of NRP1 in 143B-shNRP2 
cells further reduced VEGF-A165 stimulated AKT 
phosphorylation significantly (P ≤ 0.05) by 
approximately 50% compared to non-blocked 
cells. Thus, shRNA-mediated downregulation of 
either NRP1 or NRP2 combined with antibody-
blocking of the other NRP in 143B cells inhibit-
ed VEGF-A165 stimulated AKT phosphorylation 
similarly but not completely. Further targeting 
NRP1 alone by either shRNA or a blocking anti-
body was more effective than targeting NRP2 
alone. 
Discussion
Neoadjuvant chemotherapy in OS increased 
the long-term survival of patients with localized 
Figure 4. VEGF receptor activation stimulates NRP1/NRP2 dependent phosphorylation of AKT: Cells, serum-starved 
for 48 h and preincubated for 1 h with 20 µg/ml antibodies blocking NRP1 (α-NRP1) or NRP2 (α-NRP2), were stimu-
lated with 10 ng/µl VEGF for 5 min. Western blot analysis (left) of AKT phosphorylation and expression of NRP1 and 
NRP2 after incubation in the absence and presence of VEGF and of α-NRP1 or α-NRP2 and densitometric quanti-
fication of phospho-AKT on Western blots of 3 independent experiments (*p ≤ 0.05) carried out with the indicated 
cell lines (right): (A) 143B cells, (B) HuO9-M132 cells, (C) 143B cells transduced with NRP1 silencing (shNRP1) or 
control (scr) RNA, (D) 143B cells transduced with NRP2 silencing (shNRP2) or scr RNA. 
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disease considerably from between 20 and 
30% to approximately 60%, but metastasizing 
OS remained largely treatment resistant. Co- 
nsequently, there is a need for reliable outcome 
predictive markers in primary tumor tissue and 
for more effective, tumor-selective and -tailored 
treatment modalities particularly in metastasiz-
ing OS. 
Several recent studies showed that the expres-
sion of VEGF in OS tumor tissue is a strong 
prognostic indicator for poor overall survival of 
affected patients [31-33], but biological roles 
of VEGF signalling targets and components in 
OS have so far not been investigated. NRPs 
have been reported to be important for VEGF 
dependent hyper-vascularisation in tumour 
angiogenesis [8] and they were found to act as 
co-receptors for different pro-angiogenic iso-
forms of VEGF in ternary VEGF/NRP/VEGFR 
complexes [20, 22]. In the present study, NRP1 
and NRP2 were therefore evaluated as addi-
tional prognostic indicators and potentially 
novel tumour-selective treatment targets in OS. 
The analysis of NRP1 and/or NRP2 immunos-
taining in a tissue micro array of 66 OS patients 
indeed identified NRP2 as an indicator of poor 
overall, metastases-free and progression-free 
survival, whereas NRP1 immunostaining had 
no predictive value. Interestingly, a recent study 
with RNA isolated from tumor tissue of 30 OS 
patients also revealed a correlation between 
increased NRP2 mRNA expression and poor 
patient survival [42]. More detailed Kaplan-
Meier analyses of the TMA results in the pres-
ent study even indicated that patients with 
tumors that expressed NRP2 in the absence of 
NRP1 had a significantly worse prognosis than 
the patients with NRP1 and -2 negative, NRP1 
positive or NRP1 and -2 positive tumors. Mo- 
reover, patients with overt metastases and with 
NRP2 immunostaining in their primary tumors 
had a significantly shorter survival rate than 
patients with metastases but NRP2-negative 
tumors. This observation is particularly inter-
esting because the presence of metastases in 
OS patients is well established as the most reli-
able predictor for poor survival. Thus, the 
results of this and the study by Handa et al. [42] 
suggest a crucial role of NRP2 in OS tumor pro-
gression and metastasis. This conclusion, for 
unexplained reasons, is however inconsistent 
with the results of a recent study that described 
NRP1 as an important prognostic marker in OS 
[43].
To further explore functions of NRP1 and NRP2 
in VEGF signalling in OS and a putative biologi-
cal relevance in OS progression and metasta-
sis, we investigated the expression profiles of 
the neuropilins and of VEGF isoforms and 
receptors in several osteosarcoma cell line sys-
tems consisting of cell lines with low or high 
metastatic phenotypes. Interestingly, in two 
out of three cell line systems and in seven out 
of the ten cell lines investigated, the expression 
of both NRP1 and NRP2 at the mRNA and the 
protein level correlated to a variable degree 
with the metastatic potential of the respective 
cell line, suggesting a biological relevance of 
NRP1 and NRP2 in the metastatic process. A 
correlation between NRP expression and tumor 
aggressiveness and metastatic potential was 
also observed in a variety of solid tumors. 
Up-regulated expression of NRP1 correlated 
with metastatic phenotypes of prostate tumors 
[44] and in human colon cancer NRP1 plays a 
role in migration of cancer cells [45]. In non-
small cell lung carcinoma co-expression of 
Neuropilin 1 and Neuropilin 2 correlated signifi-
cantly with a poor prognosis for the patients 
[46]. A similar observation was made in other 
tumors such as renal cancer where NRP2 was 
found indicative for metastasis and overall sur-
vival [47]. 
NRP1 and NRP2 alone have been reported to 
be unable to mediate VEGF signaling. However, 
upon binding of particular proangiogenic VEGF 
A isoforms, NRPs bind to VEGFR both directly 
and via VEGF thereby forming a ternary com-
plex. Even though VEGFA/VEGFR complexes 
alone are able to activate the AKT signaling 
cascade, additional binding of NRPs results in 
the formation of a stable ternary complex that 
enhances VEGFR signaling. It is important to 
note that in endothelial cells NRP1 is able to 
activate AKT signaling in the absence of the 
VEGFR2, which points to additional mecha-
nisms of VEGF signaling in this particular cell 
type [48]. Here we have investigated in the 
panel of the ten OS cell lines the expression of 
the VEGFRs 1 and - 2 and of the VEGFA iso-
forms VEGF 121, 145, 165 and 206 known to 
bind to Neuropilins [22]. Among the four VEGFA 
splice variants, VEGF 121 and 165 encoding 
transcripts were rather uniformly expressed in 
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all cell lines investigated, whereas VEGF 154 
and 206 transcripts were expressed more het-
erogeneously and at lower levels. The findings 
were consistent with rather uniform levels of 
VEGFA immunoreactive components detected 
in extracts of all cell lines. The uniform and 
ubiquitous expression of VEGF 165 is of par-
ticular interest because it is known as the most 
potent VEGFA isoform and the only one which 
interacts with both NRP1 and -2 [22, 41]. The 
observed robust expression of VEGFA isoforms 
in OS cell lines is also of relevance because it 
has been shown that up-regulated expression 
of VEGFA promotes metastasis in various tumor 
types [49]. At the level of receptors, VEGFR1 
was found expressed at the transcript and pro-
tein levels in all cell lines examined with a ten-
dency for higher expression levels in the meta-
static sublines. RT/PCR products amplified 
from VEGFR2 transcripts were only recognized 
in the HOS cell line system, but, surprisingly, 
protein products remained undetectable. 
Altogether, the analysis in the three OS cell line 
systems showed robust expression of proan-
giogenic VEGFA isoforms and of the receptor 
components needed for efficient VEGF signal-
ing particularly in the highly metastatic cell 
lines. 
Consequently, such cell lines provided ideal 
experimental systems to investigate the func-
tional relevance of NRP1 and -2 in VEGF signal 
transduction.  This was examined in the pres-
ent study with NRP1 and -2 ligand-blocking 
antibodies in the metastatic 143B and 
HuO9-M132 cell lines and by shRNA mediated 
downregulation of NRP1 and -2 combined with 
the ligand-blocking antibodies in the 143B cell 
line. Interestingly, in 143B cells VEGFA signal-
ing, monitored by AKT phosphorylation, was 
more effectively inhibited by blocking or down-
regulation of NRP1 than of NRP2, whereas in 
HuO9-M132 cells NRP2 blocking antibodies 
were more effective than antibodies blocking 
NRP1. This finding in HuO9-M132 cells was 
consistent with considerably higher expression 
levels of NRP2 than of NRP1, whereas in 143B 
cells NRP1 and -2 were expressed at compara-
ble levels. Consequently, inhibition of VEGFA 
signaling by combined antibody blocking and 
shRNA-mediated downregulation of NRP1 and 
NRP2 was carried out in 143B cells. These 
experiments demonstrated that NRP1 target-
ing in 143B cells inhibited AKT phosphorylation 
more effectively than blocking or downregula-
tion of NRP2, confirming the result of the anti-
body blocking experiment. The data also indi-
cated that NRP1 and -2 can substitute each 
other in the functional interaction with VEGFR1 
with an apparently predominant role of NRP1 in 
143B cells. 
In conclusion, the expression of NRP2 in OS pri-
mary tumors was found to be a strong indicator 
for a poor prognosis for the patients. This even 
applied to patients with metastatic disease, to 
date the strongest predictor of survival in OS 
patients. Selective targeting of NRP1 or -2 with 
respective blocking antibodies in OS cell lines 
showed a cell line-dependent modulation of 
VEGF signaling by the individual NRPs. Putative 
distinct roles of NRP1 and NRP2 in OS patho-
physiology remain to be investigated in more 
detail in future studies. The observed co-
expression of NRP1, -2 and VEGFR1 in OS cell 
lines points to tumor promoting mechanisms of 
this signaling system other than VEGF-depe- 
ndent hyper-vascularization in tumor angiogen-
esis. Such mechanisms may include a reported 
NRP2-mediated upregulation of metastatic 
genes through a mechanism involving β-catenin 
[50]. This and the results of the present and 
other recent studies point to NRP2 as a power-
ful prognostic marker in OS and, together with 
NRP1, as a novel target for tailored tumor-sup-
pressive treatment. 
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Supplemental Table 1. List of primers used in PCR
Gene Oligonucleotide sequences
NRP1 full length Forward 5’-CTTGGTGGGATTGCTGTGGATGACATTAGT-3’
Reverse 3’-ATCTGGGGTAGGAGTAGTGGTAGTATCGG-5’
NRP2 full length Forward 5’-CCCAGCTACGACATGGAGTACCAGATT-3’
Reverse 3’-GCCGAAAACGTCCACTCTTAAAATTTCACC-5’
VEGF-A Forward 5’-TGCCTTGCTGCTCTACCTCC-3’
Reverse 3’-CACTGTTCGGCTCCGCCACT-5’
VEGFR-1 Forward 5’-ATGAGCAGTGTGAGCGGCTCCC-3’
Reverse 3’-CGCAGTGGTCGTCGCTTTCGAA-5’
VEGFR-2 Forward 5’-CGTCATGGATCCAGATGAACTCCC-3’
Reverse 3’-GGTTTCCCCGTGCTAAGGCAGTTC-5’
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Supplemental Figure 1. Example cores from TMA showing week, moderate and strong staining of NRP1 (left side) 
and NRP2 (right side).
